274 related articles for article (PubMed ID: 19469647)
1. Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review.
Behtash N; Hashemi R; Karimi Zarchi M
Asian Pac J Cancer Prev; 2009; 10(1):163-6. PubMed ID: 19469647
[TBL] [Abstract][Full Text] [Related]
2. Malignant mixed Mullerian tumour of uterus secondary to tamoxifen therapy for hormone responsive breast cancer.
Gupta M; Kiruthiga KG
BMJ Case Rep; 2015 Jun; 2015():. PubMed ID: 26123463
[TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen on the cervix and uterus in women with breast cancer: experience with Iranian patients and a literature review.
Karimi Zarchi M; Behtash N; Sekhavat L; Dehghan A
Asian Pac J Cancer Prev; 2009; 10(4):595-8. PubMed ID: 19827876
[TBL] [Abstract][Full Text] [Related]
4. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
Hubalek M; Ramoni A; Mueller-Holzner E; Marth C
Gynecol Oncol; 2004 Oct; 95(1):264-6. PubMed ID: 15385144
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
6. High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.
Sesti F; Patrizi L; Ermini B; Palmieri G; Orlandi A; Piccione E
Gynecol Obstet Invest; 2005; 60(2):117-20. PubMed ID: 15920338
[TBL] [Abstract][Full Text] [Related]
7. Uterine pleomorphic rhabdomyosarcoma in a patient receiving tamoxifen therapy.
Okada DH; Rowland JB; Petrovic LM
Gynecol Oncol; 1999 Dec; 75(3):509-13. PubMed ID: 10600318
[TBL] [Abstract][Full Text] [Related]
8. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Zhu Y; Yang J
J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
[TBL] [Abstract][Full Text] [Related]
9. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries.
Jones ME; van Leeuwen FE; Hoogendoorn WE; Mourits MJ; Hollema H; van Boven H; Press MF; Bernstein L; Swerdlow AJ
Breast Cancer Res; 2012 Jun; 14(3):R91. PubMed ID: 22691381
[TBL] [Abstract][Full Text] [Related]
10. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature.
Fotiou S; Hatjieleftheriou G; Kyrousis G; Kokka F; Apostolikas N
Anticancer Res; 2000; 20(3B):2015-20. PubMed ID: 10928144
[TBL] [Abstract][Full Text] [Related]
11. [Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report].
Saim M; Cote JF; Morel O; Malartic C; Akerman G; Gray F; Barranger E
Gynecol Obstet Fertil; 2008 Feb; 36(2):166-168. PubMed ID: 18249575
[TBL] [Abstract][Full Text] [Related]
12. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
13. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
Magriples U; Naftolin F; Schwartz PE; Carcangiu ML
J Clin Oncol; 1993 Mar; 11(3):485-90. PubMed ID: 8383191
[TBL] [Abstract][Full Text] [Related]
14. Uterine malignant mixed Müllerian tumor after adjuvant tamoxifen treatment for breast cancer.
Grigoriadis C; Androutsopoulos G; Zygouris D; Arnogiannaki N; Terzakis E
Eur J Gynaecol Oncol; 2013; 34(1):94-8. PubMed ID: 23590011
[TBL] [Abstract][Full Text] [Related]
15. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
16. [Tamoxifen and breast cancer].
Nechushtan H; Peretz T
Harefuah; 2002 Aug; 141(8):718-20, 761, 760. PubMed ID: 12222137
[TBL] [Abstract][Full Text] [Related]
17. [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases].
Le Bouëdec G; Auvray H; Curé H; de Latour M; Penault-Llorca F; Dauplat J
Rev Med Interne; 2001 Sep; 22(9):881-5. PubMed ID: 11599191
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
[TBL] [Abstract][Full Text] [Related]
19. Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
Botsis D; Koliopoulos C; Kondi-Pafitis A; Creatsas G
Int J Gynecol Pathol; 2006 Apr; 25(2):173-5. PubMed ID: 16633068
[TBL] [Abstract][Full Text] [Related]
20. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F
Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
